Matthew graduated from North Carolina State University in 2016 with his B.S. in Chemistry. As an undergraduate, he worked with Dr. Joshua Pierce on the total synthesis of alotamide A with applications to chemical probes for neurological disease. Further, Matthew conducted a summer research fellowship at Memorial Sloan Kettering Cancer Center under the direction of Dr. Derek Tan, in which he focused on the development of a synthetic method towards benzannulated medium-sized ring scaffolds. Matthew joined the Hergenrother lab in December of 2016 as a NIH Chemistry-Biology Interface fellow and Roger Adams Fellow. His work is focused on the synthesis and discovery of novel mutation-specific cancer therapeutics.
Overcoming resistance to targeted anticancer therapies through small-molecule mediated MEK degradation
Peh, J.; Boudreau, M. W.; Smith, H. M.; and Hergenrother, P. J.
Cell Chem. Biol.2018, published on web June 14, 2018.